Showing Results for
- Academic Journals (97)
Search Results
- 97
Academic Journals
- 97
-
From:Canadian Urological Association Journal (Vol. 8, Issue 9-10) Peer-ReviewedIntroduction Prostate cancer growth is fuelled by androgens; physiological levels of androgens stimulate prostate cancer proliferation and inhibit apoptotic death.1 Androgen deprivation therapy is first-line...
-
From:Oncology (Vol. 35, Issue 1) Peer-ReviewedEnzalutamide treatment presented a clinically meaningful 27% lower risk of death than placebo for patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to a presentation from the virtually...
-
From:Oncology (Vol. 35, Issue 4) Peer-ReviewedThe authors of the accompanying article present a call to action to redefine historically characterized prostate cancer disease states to a contemporary model that emphasizes earlier interventions to prevent disease...
-
From:Indian Journal of Urology (Vol. 38, Issue 2) Peer-ReviewedByline: Swarnendu. Mandal The Survival Disadvantage of Lymph Node Dissection in Nonmetastatic Renal Cell Carcinoma The current European Association of Urology guidelines for nonmetastatic renal cell carcinoma (RCC)...
-
From:Nature (Vol. 523, Issue 7560) Peer-ReviewedProstate cancer resistance to castration occurs because tumours acquire the metabolic capability of converting precursor steroids to 5a-dihydrotestosterone (DHT), promoting signalling by the androgen receptor and the...
-
From:Indian Journal of Surgery (Vol. 82, Issue 6) Peer-ReviewedMetastatic prostate cancer is a hormone sensitive cancer. For patients with prostate cancer, general surgeons and urologists are the points of first contact. Historically, restricted treatment options meant that such...
-
From:Gene Therapy (Vol. 27, Issue 1-2) Peer-ReviewedFor patients with metastatic prostate cancer, the 5-year survival rate of 31% points to a need for novel therapies and improvement of existing modalities. We propose that p53 gene therapy and chemotherapy, when...
-
From:Canadian Urological Association Journal (Vol. 7, Issue 2Suppl1) Peer-ReviewedAuthor(s): Jamil Asselah, MD, Catherine Sperlich, MD, FRCPC Introduction As recently as the beginning of the 21st century, metastatic castration-resistant prostate cancer (mCRPC) had a bleak prognosis. The...
-
From:Nature (Vol. 533, Issue 7604) Peer-ReviewedAbiraterone blocks androgen synthesis and prolongs survival in patients with castration-resistant prostate cancer, which is otherwise driven by intratumoral androgen synthesis (1,2). Abiraterone is metabolized in...
-
From:Indian Journal of Urology (Vol. 36, Issue 1) Peer-ReviewedByline: Gautam. Kumar Summary LATITUDE was a multicenter, randomized, double-blind, phase 3 trial on high-risk metastatic castration-sensitive prostate cancer (mCSPC).[1] The inclusion criteria were men who fulfilled...
-
From:Canadian Urological Association Journal (Vol. 14, Issue 12) Peer-ReviewedIntroduction: Abiraterone acetate plus prednisone (AA+P) has shown to significantly improve survival. COSMiC, a Canadian Observational Study in Metastatic Cancer of the Prostate, set out to prospectively amass...
-
From:Journal of Experimental & Clinical Cancer Research (Vol. 41, Issue 1) Peer-ReviewedProstate cancer is a hormone-driven disease and its tumor cell growth highly relies on increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against androgen synthesis or AR activation is...
-
From:Prostate Cancer (Vol. 2021) Peer-ReviewedObjectives. To determine whether an alkaline phosphatase (ALP) flare after androgen deprivation therapy (ADT) is associated with the treatment response in castration-resistant prostate cancer (CRPC) and predicts the...
-
From:Indian Journal of Urology (Vol. 35, Issue 3) Peer-ReviewedByline: Apul. Goel Abiraterone for Localized High-Risk Prostate Cancer The management of localized high-risk prostate cancer (LHRPC) remains challenging with high recurrence rates reported with presently available...
-
From:Mayo Clinic Proceedings (Vol. 95, Issue 4) Peer-ReviewedA 61-year-old man with a medical history of coronary artery disease and symptomatic urolithiasis presented to the emergency department with new onset gross hematuria and 3 months of low back pain, urinary symptoms, and...
-
From:PLoS ONE (Vol. 13, Issue 4) Peer-ReviewedBackground The objective of this study was to conduct an indirect treatment comparison between cabazitaxel, abiraterone and enzalutamide to determine the clinical efficacy and safety of cabazitaxel relative to...
-
From:PLoS ONE (Vol. 16, Issue 12) Peer-ReviewedAuthor(s): Stephanie I. Kim, Andy H. Szeto, Katherine P. Morgan, Blaine Brower, Mary W. Dunn, Amir H. Khandani, Paul A. Godley, Tracy L. Rose, Ethan M. Basch, Matthew I. Milowsky, Young E Whang, Daniel J Crona The...
-
From:Oncology (Vol. 35, Issue 12) Peer-ReviewedLEARNING OBJECTIVES Upon successful completion of this activity, you should be better prepared to: * Describe the mechanism of action of proteolysis-targeting chimera (PROTAC) therapy for the treatment of cancer. *...
-
From:Oncology (Vol. 35, Issue 11) Peer-ReviewedBACKGROUND: PARP inhibitors have been recently approved by the FDA for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Their effectiveness is seen when used with androgen deprivation therapy in...
-
From:Journal of Clinical Investigation (Vol. 130, Issue 4) Peer-ReviewedThe genomics of primary prostate cancer differ from those of metastatic castration-resistant prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer biopsies from patients who developed mCRPC,...